PTO/SB/08a (01-08) Approved for use through 07/31/2008. OMB 0651-0031

0290494.00122US1

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to reond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1/49A/PTO Application Number 10/595,485-Conf. #1304 INFORMATION DISCLOSURE Filing Date September 6, 2007 STATEMENT BY APPLICANT First Named Inventor Ezio GHIGO 1646 Art Unit (Use as many sheets as necessary) Not Yet Assigned Examiner Name

Attorney Docket Number

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2</sup> ( If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
-					
				×	
-	-				

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>A</sup> -Kind Code <sup>5</sup> (# known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	To
	BA	WO-01/56592	08-09-2001	Novo Nordisk A/S		
						$\Box$
						Ш
						ш

Examiner Signature	Date Considered	

"EXAMINER: Initial if reference considered, whether or not clustion is in conformance with MPEP 609. Draw time through citation of not in conformance and not considered. Include copy of the flow flow with need communication to applicant." Applicant's unique actions disequipation number (optional). "See Kinst Codes of USPTO Patriot Discussion at a large action disequipation and the conformation of the patriot." First offician that issued the document, by the two-latter code (WPD Standard ST.3). "For Japaneses patriot document, in a including on the indication of the year of the negle of the Empirer must proceed his aerial number of the patriot document." Kind of document by the appropriate symbols as indicated for the document under ST.1 off possible." Applicant is to place a choice mark their Children draws and the conservation of WPD Standard ST.1 off possible." Applicant is to place a choice mark their Children draws and the conformation of the conservation of the ST.1 off possible." Applicant is to place a choice mark their Children draws and the conservation of the Children of the Translation is attached

Sheet

1

of

6

PTO/SB/08b (01-08)
Approved for use through 07/31/2008. CMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/595,485-Conf. #1304	
INFORMATION DISCLOSURE			SCLOSURE	Filing Date	September 6, 2007	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ezio GHIGO	
				Art Unit	1646	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	6	Attorney Docket Number	0290494.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	ARIYASU, H. et al., "Stomach is a Major Source of Circulating Ghrelin, and Feeding State Determines Plasma Ghrelin-Like Immunoreactivity Levels in Humans", The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 10 (2001) pp. 4753-4758	
	СВ	BEDNAREK, M. A. et al., "Structure - Function Studies on the New Growth Hormone- Releasing Peptide Ghrelin: Minimal Sequence of Ghrelin Necessary for Activation of Growth Hormone Secretagogue Receptor 1a", J. Med. Chem, Vol. 43 (2000) pp. 4370-4376	
	сс	CAIXAS, A. et al., "Insulin, unlike Food Intake, does not Suppress Ghrelin in Human Subjects", The Journal of Clinical Endocrinology & Metabolism, Vol. 87, No. 4 (2002) pp. 1902-1906	
	CD	CHAPMAN, I. et al. "Enhancement of Pulsatile Growth Hormone Secretion by Continuous Infusion of a Growth Hormone-Releasing Peptide Mimetic, L692,429, in Older Adults - A Clinical Research Center Study." Journal of Clinical Endocrinology and Metabolism, Vol. 81, No. 8 (1999) pp. 2874-2880.	
	CE	CHAPMAN, I. et al., "Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults", Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 10 (1997) pp. 3455-3463	Г
	CF	CUMMINGS, D. E. et al., "A Preprandial Rise in Plasma Ghrelin Levels Suggests a Role in Meal Initiation in Humans", Diabetes, Vol. 50 (August 2001) pp. 1714-1719	
	CG	DATE, Y. et a., "Ghrelin Acts in the Central Nervous System to Stimulate Gastric Acid Secretion", Biochemical and Biophysical Research Communications, Vol. 280 (2001) pp. 904-907	
	СН	DATE, Y. et al., "Ghrelin is Present in Pancratic α-Cells of Humans and Rats and Stimulates Insulin Secretion", Diabetes, Vol. 51 (January 2002) pp. 124-129	
	CI	DATE, Y. et al., "Shrelin, a Novel Growth Hormone-Released Acylated Peptide, Is Synthesized in a Distinct Endocrine Cell Type in the Gastrointestinal Tracts of Rats and Humans." Endocrinology, Vol. 141, No. 11 (2000) pp. 4255-4261	
	CJ	European Office Action, corresponding to European Application No. 02787266.2, October 7, 2008	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Beneauck Reduction Act of 1995, no. of

Sut	astitute for form 1449/PTO			Complete if Known		
				Application Number	10/595,485-Conf. #1304	
IN.	<b>NFORMATION</b>	I DI	SCLOSURE	Filing Date	September 6, 2007	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ezio GHIGO	
				Art Unit	1646	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	6	Attorney Docket Number	0290494.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbor(s), publisher, city and/or country where published.	T <sup>2</sup>
	ск	FURUSE, M. et al., "Intracerebroventricular injection of ghrelin and growth hormone releasing factor inhibits food intake in neonatal chicks", Neuroscience Letters, Vo. 301 (2001) pp. 123-126	
	CL	GUALILLO et al. "Ghrelin, A Novel Placental-Derived Hormone", Endocrinology, Vol. 142, No. 2, (2001) pp. 788-794	
	СМ	HATTORI et al. "GH. GH Receptor, GH Secretagogue Receptor, and Ghrelin Expression in Human T Cells, B Cells, and Neutrophils." The Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 9 (2001) pp. 4284-4291	
	CN	HORVATH, T. L. et al., "Minireview: Ghrelin and the Regulation of Energy Balance - A hypothalamic Perspective", Endocrinology, Vol. 142, No. 10 (2001) pp. 4163-4169	
	со	INUI, Akio, "Ghrelin: An orexigenic and Somatotrophic Signal from the Stomach", Nature Reviews, Vol. 2 (August 2001) pp. 1-10	
	СР	KAMEGAI, J. et al., "Central Effect of Ghrelin, an Endogenous Growth Hormone Secretagogue, on Hypothalamic Peptide Gene Expression", Endocrinology, Vol. 141, No. 12, 2000, pp. 4797-4800	
	cq	KAMEGAI, J. et al., "Chronic Central Infusion of Ghrelin Increases Hypothalamic Neuropeptide Y and Agouti-Related Protein mRNA Levels and Body Weight in Rats", Diabetes, Vol. 40 (November 2001) pp. 2438-2443	
	CR	KOJIMA et al. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach" Nature, Vol. 402, 9 December 1999. (pp 656-660)	
	cs	IKORBONITS et al. "The presence of ghrelin in normal and adenomatous human pituitary." Department of Endocrinology, St. Batholomew's Hospital, London, UK and Department of Biochangistry, National Cardiovascular Center Institute, Fujishirodau, Suita, Osaka Japan (11 pgg) 2009	
	ст	LUCIDI, P. et al., "Ghrelin is not Necessary for Adequate Hormonal Counterregulation of Insulin-Induced Hypoglycemia", Diabetes, Vol. 51 (October 2002) pp. 2911-2914	

CS Department of Endocrinology, St. Bartholomew's Hospital, London, UK and Department of Biochemistry, National Cardiovascular Center Institute, Fujishirodau, Suita, Osaka Japan (11 pgs) 2009				
	СТ	LUCIDI, P. et al., "Ghrelin is not Necessary for Adequate Hormonal Counterregulation of Insulin-Induced Hypoglycemia", Diabetes, Vol. 51 (October 2002) pp. 2911-2914		
Exami		Date Considered	$\overline{\neg}$	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Papplicant is to place a check mark here if English language Translation is attached. 09/25/2009

PTO/SB/08b (01-08)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sut	astitute for form 1449/PTO			Complete if Known		
				Application Number	10/595,485-Conf. #1304	
IN.	NFORMATION	I DI	SCLOSURE	Filing Date	September 6, 2007	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ezio GHIGO	
				Art Unit	1646	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	4	of	6	Altomey Docket Number	0290494.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CU	MASUDA, Y. et al., "Ghrelin Stimulates Gastric Acid Secretion and Motility in Rats", Biochemical and Biophysical Research Communications, Vol. 276 (2000) pp. 905-908	
	cv	MATSUMOTO, M. et al., "Structure-Activity Relationship of Ghrelin: Pharmacological Study of Ghrelin Peptides", Biochemical and Biophysical Research Communications, Vol. 287 (2001), pp. 142-145	
	cw	MORI, K. et al., "Kidney produces a novel acylated peptide, ghrelin", FEBS Letters, Vol. 486 (2000) pp. 213-216	
	сх	MUCCIOLI, G. et al. "Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity," European Journal of Pharmacology, Vol. 440 (2002) pp. 235-254	
	CY	MUCCIOLI, G. et al., "Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland", J. Endocrinol. Invest., Vol. 24 (2001) pp. RC7-RC9	
	cz	MULLER, A. F. et al., "Blockade of the Growth Hormone (GH) Receptor Unmasks Rapid GH- Releasing Peptide-6-Mediated Tissue-Specific Insulin Resistance", The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 2, 2001, pp. 590-593	
	CA1	NAGAYA, N. et al., "Hemodynamic and hormonal effects of human ghrelin in healthy volunteers", Am J. Physiol Regulatory Integrative Comp. Physiol., Vol. 280 (2001) pp. R1483-R1487	
	CB1	NAKAGAWA, E. et al., "Hyperglycaemia suppresses the secretion of ghrelin, a novel growth- hormone-releasing peptide: responses to the intravenous and oral administration of glucose". Clinical Science, Vol. 103 (2002) pp. 325-328	
	CC1	OKUMURA, H. et al., "Vasodilatory Effect of Ghrelin, an Endogenous Peptide from the Stomach", Journal of Cadiovascular Pharmacology, Vol. 39 (2002) pp. 779-783	
	CD1	PAGOTTO, U. et al., "Plasma Ghrelin, Obesity, and the Polycystic Ovary Syndrome: Correlation with Insulin Resistance and Androgen Levels", The Journal of Clinical Endocrinology & Metabolism, Vol. 87, No. 12 (2002) pp. 5625-5629	Г

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)
Approved for use through 07/31/2008. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/595,485-Conf. #1304	
IN.	NFORMATION	I DI	SCLOSURE	Filing Date	September 6, 2007	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ezio GHIGO	
				Art Unit	1646	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	5	of	6	Altomey Docket Number	0290494.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CE1	SAAD, M. et al., "Insulin Regulates Plasma Ghrelin Concentration", The Journal of Clinical Endocrinology & Metabolism, Vol. 87, No. 8 (2002) pp. 3997-4000	
	CF1	SVENSSON, J. et al., "Two-Month Treatment of Obeas Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expendiure", Journal of Clinical Endocrinology and Metabolism. Vol. 83, No. 2 (1998) pp. 362- 369	
	CG1	TANKA, M. et al., "Testis-specific and developmentally induced expression of a ghrelin gene- deprived transcript that encodes a novel polypeptide in the mouse", Biochimica et Biophysica Acta, Vol. 1522 (2001) pp. 62-65	
	CH1	TENA-SEMPERE, M. et al., "Novel Expression and Functional Role of Ghrelin in Rat Testis", Endocrinology, Vol. 143, No. 2, 2002, pp. 717-725	
	CI1	TOLLE, V. et al., "Ultradian Rhythmicity of Ghrelin Secretion in Relation with GH, Feeding Behavior, and Sleep-Wake Patterns in Rats", Endocrinology, Vol. 143, No. 4 (2002) pp. 1353-1361	
	CJ1	TSCHOP, M. et al., "Ghrelin induces adiposity in rodents", Letters to Nature, Vol. 407 (19 October 2000) pp. 908-913	
	СК1	VOLANTE, et al. "Extensive DNA Fragmentation in Oxyphilic Cell Lesions of the Thyroid," The Journal of Histochemistry and Cytochemistry, Vol. 49, No. 8 (2001) pp. 1003-1011	
	CL1	VOLANTE, M. et al., "Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors", The Journal of Clinical Endocrinology & Metabolism, Vol. 87, No. 3 (2002) pp. 1300-1308	
	CM1	VOLANTE, M. et al., "Ghrelin Expression in Fetal, Infant, and Adult Human Lung", The Journal of Histochemistry & Cytochemistry, Vol. 50, No. 8 (2002) pp. 1013-1021	
	CN1	WIERUP, N. et al., "The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas", Regulatory Peptides, Vol. 107 (2002) pp. 63-69	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

08/18/2009

Approved for use through 07/31/2006. DMI 0651-0031

U.S. Patenta and Trademark Office; U.S. DEPARTIMENT OF COMMERCE
Using the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unites its contains a valid OMS control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/595,485-Conf. #1304	
IN.	<b>IFORMATION</b>	I DI	SCLOSURE	Filing Date	September 6, 2007	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ezio GHIGO	
				Art Unit	1646	
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	6	of	6	Altomey Docket Number 0290494.00122US1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CO1	WREN, A. M. et al., "Ghrelin Enhances Appetite and Increases Food Intake in Humans", The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 12 (2001) pp. 5992-5995	
	CP1	WREN, A.M. et al., "The Novel Hypothalamic Peptide Ghrelin Stimulates Food Intake and Growth Hormone Secretion", Endocrinology, Vol. 141, No. 11 (2000) pp. 4325-4328	П
	CQ1	YOSHIHARA, F. et al., "Ghrelin: a novel peptide for growth hormone release and feeding regulation", Genes and Nutrition, pp. 391-395	П
	CR1	ZHANG, W. et al., "Inhibition of pancreatic protein secretion by ghrelin in the rat", Journal of Physiology, Vol. 537, No. 1 (2001) pp. 231-236	
			Н
			Н
			$\Box$
			$\mathbf{L}$

Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Constitute the same of	
considered. Include copy of this form with next communication to applicant.		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner

/Gyan Chandra/